Physician profile
Richard B Warner
NPI 1396950507
$7,366.08
in general payments reported to CMS, 2019-2025
23 companies · $57.29 in 2025
The $57.29 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $114 · 2021: $336 · 2022: $344 · 2023: $2,367 · 2024: $3,765 · 2025: $57.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,189.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.82 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lundbeck LLC | $1,015.91 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $755.52 | 2022-2024 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $738.19 | 2019-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $373.03 | 2019-2024 | Trintellix |
| Tris Pharma INC | $368.62 | 2023-2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.66 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $298.53 | 2022-2024 | Austedo Xr |
| Corium, LLC | $287.82 | 2023-2024 | Azstarys |
| Almatica Pharma LLC | $279.93 | 2023-2024 | Loreev Xr |
| Noven Therapeutics, LLC | $261.99 | 2023-2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $246.86 | 2023-2024 | Jornay Pm |
| Bausch Health US, LLC | $185.66 | 2023-2024 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $168.40 | 2022-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $136.14 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $106.88 | 2020-2024 | Hetlioz, Fanapt |
| Tempus Ai, INC | $75.74 | 2024 | |
| Janssen Pharmaceuticals, INC | $70.46 | 2023-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $67.39 | 2023-2024 | Quviviq |
| Alkermes, INC. | $46.65 | 2024 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $19.77 | 2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $18.41 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $14.70 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.